Pediatric Skin Research LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$845,894	121
2024	Research	$216,987	197
2023	Research	$347,629	165
2022	Research	$137,349	36
2021	Research	$293,381	44
2020	Research	$108,253	15

Breakdown

Who paid Research payments · program years 2020–2025

Regeneron Pharmaceuticals, Inc. $510,195 151 payments
Sanofi US Services Inc. $398,742 42 payments
Eli Lilly and Company $284,703 12 payments
Incyte Corporation $188,866 69 payments
Pfizer Inc. $179,153 16 payments
AbbVie, Inc. $174,518 36 payments
Dermavant Sciences, Inc. $136,139 251 payments
Amgen Inc. $77,178 1 payment

Studies the money was for Research payments · program years 2020–2025

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months to <18 Years of Age With Atopic Dermatitis $319,645 119 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $192,141 11 payments
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $162,377 6 payments
A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to <6 Years With Severe Atopic Dermatitis $161,525 26 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $101,582 2 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $90,048 2 payments
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis $77,178 1 payment
A Phase 3 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Ritlecitinib in Pediatric Participants 6 to Less Than 12 Years of Age With Severe Alopecia Areata $75,696 4 payments
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo $73,840 18 payments
An Interventional PK PD Phase 1 Openlabel Study to Investigate PK and PD of Multipledose Ritlecitinib in Children 6 to Less Than 12 Years of Age With Severe Alopecia Areata $72,987 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.